vs
LANDSTAR SYSTEM INC（LSTR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
LANDSTAR SYSTEM INC的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 3.4%，领先9.4%），Revvity同比增速更快（5.9% vs 1.6%），过去两年Revvity的营收复合增速更高（9.0% vs -2.2%）
Landstar System Inc.是美国专业运输服务企业，主营第三方物流业务，依托由超8800名独立自营车主、1000余名独立货运代理人、7万余家合规认证承运商组成的庞大网络，服务主要覆盖美国全境，同时提供加拿大境内及美加、美墨跨境物流服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LSTR vs RVTY — 直观对比
营收规模更大
LSTR
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出4.2%
1.6%
净利率更高
RVTY
高出9.4%
3.4%
两年增速更快
RVTY
近两年复合增速
-2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $39.4M | $98.4M |
| 毛利率 | 9.6% | — |
| 营业利润率 | 4.5% | 14.5% |
| 净利率 | 3.4% | 12.7% |
| 营收同比 | 1.6% | 5.9% |
| 净利润同比 | 32.3% | 3.9% |
| 每股收益（稀释后） | $1.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSTRRVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M |
净利润LSTRRVTY
| Q1 26 | $39.4M | — | ||
| Q4 25 | $23.9M | $98.4M | ||
| Q3 25 | $19.4M | $46.7M | ||
| Q2 25 | $41.9M | $53.9M | ||
| Q1 25 | $29.8M | $42.2M | ||
| Q4 24 | $46.2M | $94.6M | ||
| Q3 24 | $50.0M | $94.4M | ||
| Q2 24 | $52.6M | $55.4M |
毛利率LSTRRVTY
| Q1 26 | 9.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率LSTRRVTY
| Q1 26 | 4.5% | — | ||
| Q4 25 | 2.5% | 14.5% | ||
| Q3 25 | 2.2% | 11.7% | ||
| Q2 25 | 4.6% | 12.6% | ||
| Q1 25 | 3.4% | 10.9% | ||
| Q4 24 | 4.8% | 16.3% | ||
| Q3 24 | 5.2% | 14.3% | ||
| Q2 24 | 5.6% | 12.4% |
净利率LSTRRVTY
| Q1 26 | 3.4% | — | ||
| Q4 25 | 2.0% | 12.7% | ||
| Q3 25 | 1.6% | 6.7% | ||
| Q2 25 | 3.5% | 7.5% | ||
| Q1 25 | 2.6% | 6.4% | ||
| Q4 24 | 3.8% | 13.0% | ||
| Q3 24 | 4.1% | 13.8% | ||
| Q2 24 | 4.3% | 8.0% |
每股收益（稀释后）LSTRRVTY
| Q1 26 | $1.16 | — | ||
| Q4 25 | $0.70 | $0.86 | ||
| Q3 25 | $0.56 | $0.40 | ||
| Q2 25 | $1.20 | $0.46 | ||
| Q1 25 | $0.85 | $0.35 | ||
| Q4 24 | $1.30 | $0.77 | ||
| Q3 24 | $1.41 | $0.77 | ||
| Q2 24 | $1.48 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $411.0M | $919.9M |
| 总债务越低越好 | $26.1M | — |
| 股东权益账面价值 | $799.0M | $7.3B |
| 总资产 | $1.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.03× | — |
8季度趋势，按日历期对齐
现金及短期投资LSTRRVTY
| Q1 26 | $411.0M | — | ||
| Q4 25 | $452.2M | $919.9M | ||
| Q3 25 | $434.4M | $931.4M | ||
| Q2 25 | $426.2M | $991.8M | ||
| Q1 25 | $473.4M | $1.1B | ||
| Q4 24 | $566.6M | $1.2B | ||
| Q3 24 | $531.3M | $1.2B | ||
| Q2 24 | $504.0M | $2.0B |
总债务LSTRRVTY
| Q1 26 | $26.1M | — | ||
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益LSTRRVTY
| Q1 26 | $799.0M | — | ||
| Q4 25 | $795.7M | $7.3B | ||
| Q3 25 | $888.7M | $7.4B | ||
| Q2 25 | $921.8M | $7.6B | ||
| Q1 25 | $930.8M | $7.6B | ||
| Q4 24 | $972.4M | $7.7B | ||
| Q3 24 | $1.0B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B |
总资产LSTRRVTY
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $12.2B | ||
| Q3 25 | $1.7B | $12.1B | ||
| Q2 25 | $1.7B | $12.4B | ||
| Q1 25 | $1.7B | $12.4B | ||
| Q4 24 | $1.8B | $12.4B | ||
| Q3 24 | $1.8B | $12.8B | ||
| Q2 24 | $1.8B | $13.4B |
负债/权益比LSTRRVTY
| Q1 26 | 0.03× | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流LSTRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $72.7M | $182.0M | ||
| Q3 25 | $89.3M | $138.5M | ||
| Q2 25 | $7.1M | $134.3M | ||
| Q1 25 | $55.7M | $128.2M | ||
| Q4 24 | $61.1M | $174.2M | ||
| Q3 24 | $83.1M | $147.9M | ||
| Q2 24 | $48.1M | $158.6M |
自由现金流LSTRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $70.5M | $161.8M | ||
| Q3 25 | $86.0M | $120.0M | ||
| Q2 25 | $4.7M | $115.5M | ||
| Q1 25 | $53.8M | $112.2M | ||
| Q4 24 | $54.4M | $149.8M | ||
| Q3 24 | $75.6M | $125.6M | ||
| Q2 24 | $40.6M | $136.6M |
自由现金流率LSTRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 6.0% | 21.0% | ||
| Q3 25 | 7.1% | 17.2% | ||
| Q2 25 | 0.4% | 16.0% | ||
| Q1 25 | 4.7% | 16.9% | ||
| Q4 24 | 4.5% | 20.5% | ||
| Q3 24 | 6.2% | 18.4% | ||
| Q2 24 | 3.3% | 19.7% |
资本支出强度LSTRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.2% | 2.4% | ||
| Q4 24 | 0.6% | 3.4% | ||
| Q3 24 | 0.6% | 3.3% | ||
| Q2 24 | 0.6% | 3.2% |
现金转化率LSTRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.04× | 1.85× | ||
| Q3 25 | 4.61× | 2.97× | ||
| Q2 25 | 0.17× | 2.49× | ||
| Q1 25 | 1.87× | 3.03× | ||
| Q4 24 | 1.32× | 1.84× | ||
| Q3 24 | 1.66× | 1.57× | ||
| Q2 24 | 0.91× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSTR
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
